Companies › Merck KGaA
18 active drug programs in 73 registered trials: 35 Phase 2, 26 Phase 1, 11 Phase 3, 1 Phase 4; Oncology, Immunology, Other, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Avelumab Programmed cell death 1 ligand 1 other | CD274 | Phase 3 | Solid Tumors; Locally Advanced or Metastatic Urothelial Carcinoma; Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable; HNSCC … | Nov 2026 |
| Follitropin (MBJ-0011) Follicle stimulating hormone receptor agonist | FSHR | Phase 3 | Infertility | Sep 2027 |
| Enpatoran Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist | TLR8, TLR7 | Phase 3 | Systemic Lupus Erythematosus (SLE); Systematic Lupus Erythematosus | May 2029 |
| Precemtabart tocentecan Topoisomerase I inhibitor | – | Phase 3 | Metastatic Colorectal Cancer | Oct 2029 |
| M6223 | – | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | Jan 2027 |
| NKTR-255 | – | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma; B Acute Lymphoblastic Leukemia | Jan 2027 |
| Enpatoran (M5049) Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist | TLR8, TLR7 | Phase 2 | Systemic Lupus Erythematosus | Aug 2028 |
| Pimicotinib CSF1R tyrosine kinase inhibitor | CSF1R | Phase 2 | Tenosynovial Giant Cell Tumor | Aug 2028 |
| Tepotinib Hepatocyte growth factor receptor inhibitor | MET | Phase 2 | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Advanced Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic … | – |
| Mirdametinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor | MAP2K1, MAP2K2 | Phase 1 | Healthy | Nov 2026 |
| Tuvusertib (M1774) | – | Phase 1 | Metastatic or Locally Advanced Unresectable Solid Tumors; Advanced Solid Tumor; Endometrial Cancer | Nov 2026 |
| M9466 | – | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| M3554 anti-GD2 antibody-drug conjugate | GD2 | Phase 1 | Advanced Solid Tumor | Apr 2027 |
| M5542 | – | Phase 1 | Healthy | Dec 2027 |
| M9140 anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 1 | Colorectal Cancer; Solid Tumors | Dec 2027 |
| M7437 anti-Ly6E antibody-drug conjugate with exatecan payload | LY6E | Phase 1 | Advanced Solid Tumors | Sep 2028 |
| M0324 | – | Phase 1 | Advanced Solid Tumor | Feb 2029 |
| M9140 anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 1 | Solid Tumors | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03498378 | Avelumab | Phase 1 | Head and Neck Squamous Cell Carcinoma | Oncology | Feb 2020 |
| NCT04004442 | Avelumab | Phase 1 | Urothelial Carcinoma | Oncology | Apr 2022 |
| NCT02864992 | Tepotinib | Phase 2 | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Oncology | May 2022 |
| NCT03979131 | Avelumab | Phase 2 | Gastroesophageal Junction Adenocarcinoma | Oncology | Mar 2023 |
| NCT04678362 | Avelumab | Phase 2 | Urothelial Carcinoma | Oncology | Jul 2023 |
| NCT06806046 | M9140 | Phase 1 | Solid Tumors | Oncology | Sep 2026 |
| NCT05464030 | M9140 | Phase 1 | Colorectal Cancer | Oncology | Oct 2026 |
| NCT04291885 | Avelumab | Phase 2 | Merkel Cell Carcinoma | Oncology | Nov 2026 |
| NCT02912572 | Avelumab | Phase 2 | Metastatic Endometrial Cancer | Oncology | Nov 2026 |
| NCT07840612 | Mirdametinib | Phase 1 | Healthy | Other | Nov 2026 |
| NCT03815643 | Avelumab | Phase 3 | Solid Tumors | Oncology | Nov 2026 |
| NCT04170153 | Tuvusertib (M1774) | Phase 1 | Metastatic or Locally Advanced Unresectable Solid Tumors | Oncology | Nov 2026 |
| NCT04848519 | Avelumab | Phase 2 | Locally Advanced Bladder Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT05600127 | Avelumab | Phase 2 | Urothelial Carcinoma | Oncology | Dec 2026 |
| NCT04261855 | Avelumab | Phase 1 | Metastatic Merkel Cell Carcinoma | Oncology | Dec 2026 |
| NCT03573648 | Avelumab | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT03147287 | Avelumab | Phase 2 | Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT03391479 | Avelumab | Phase 2 | Penile Cancer | Oncology | Dec 2026 |
| NCT06820255 | Avelumab | Phase 4 | Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable | Oncology | Jan 2027 |
| NCT05327530 | Avelumab | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | Oncology | Jan 2027 |
| NCT05327530 | M6223 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | Oncology | Jan 2027 |
| NCT05327530 | NKTR-255 | Phase 2 | Locally Advanced or Metastatic Urothelial Carcinoma | Oncology | Jan 2027 |
| NCT03971409 | Avelumab | Phase 2 | Stage III Breast Cancer | Oncology | Jan 2027 |
| NCT06421935 | M9466 | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT06421935 | Tuvusertib (M1774) | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2027 |
| NCT04792073 | Avelumab | Phase 2 | Merkel Cell Carcinoma | Oncology | Mar 2027 |
| NCT03076554 | Avelumab | Phase 2 | Thymoma | Oncology | Mar 2027 |
| NCT04387084 | Avelumab | Phase 1 | Advanced Malignant Skin Neoplasm | Oncology | Mar 2027 |
| NCT03964532 | Avelumab | Phase 1 | Breast Cancer | Oncology | Apr 2027 |
| NCT06641908 | M3554 | Phase 1 | Advanced Solid Tumor | Oncology | Apr 2027 |
| NCT04071236 | Avelumab | Phase 1 | Metastatic Castration-Resistant Prostate Carcinoma | Oncology | Apr 2027 |
| NCT03414658 | Avelumab | Phase 2 | Breast Cancer | Oncology | May 2027 |
| NCT06892860 | Avelumab | Phase 2 | Urinary Bladder Neoplasms | Oncology | Jun 2027 |
| NCT04068194 | Avelumab | Phase 1 | Locally Advanced Malignant Solid Neoplasm | Oncology | Jul 2027 |
| NCT04841148 | Avelumab | Phase 2 | Breast Cancer | Oncology | Jul 2027 |
| NCT04360941 | Avelumab | Phase 1 | Triple Negative Breast Cancer | Oncology | Jul 2027 |
| NCT06869473 | Avelumab | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Oncology | Aug 2027 |
| NCT06518564 | Avelumab | Phase 2 | Endometrial Cancer | Oncology | Aug 2027 |
| NCT06518564 | Tuvusertib (M1774) | Phase 2 | Endometrial Cancer | Oncology | Aug 2027 |
| NCT06228066 | Avelumab | Phase 2 | Small Cell Carcinoma of the Bladder | Oncology | Sep 2027 |
| NCT07340827 | Follitropin (MBJ-0011) | Phase 3 | Infertility | Genitourinary | Sep 2027 |
| NCT06640725 | Avelumab | Phase 2 | Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck | Oncology | Oct 2027 |
| NCT02999087 | Avelumab | Phase 3 | HNSCC | Oncology | Dec 2027 |
| NCT02767063 | Avelumab | Phase 1 | Leukemia, Myeloid, Chronic-Phase | Oncology | Dec 2027 |
| NCT06577337 | M5542 | Phase 1 | Healthy | Other | Dec 2027 |
| NCT06710132 | M9140 | Phase 1 | Solid Tumors | Oncology | Dec 2027 |
| NCT06083857 | Tepotinib | Phase 1 | Non-small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT05947500 | Avelumab | Phase 2 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Oncology | Jan 2028 |
| NCT05782361 | Tepotinib | Phase 1 | Advanced Cancer | Oncology | Mar 2028 |
| NCT06908993 | Tepotinib | Phase 3 | Advanced Non Small Cell Lung Cancer | Oncology | Mar 2028 |
| NCT06031688 | Tepotinib | Phase 2 | Recurrent Lung Non-Small Cell Carcinoma | Oncology | May 2028 |
| NCT05327686 | Avelumab | Phase 2 | Metastatic Renal Cell Carcinoma | Oncology | Jun 2028 |
| NCT05540327 | Enpatoran (M5049) | Phase 2 | Systemic Lupus Erythematosus | Immunology | Aug 2028 |
| NCT06686381 | Avelumab | Phase 2 | Muscle-invasive Bladder Cancer | Oncology | Aug 2028 |
| NCT07499362 | Pimicotinib | Phase 2 | Tenosynovial Giant Cell Tumor | Oncology | Aug 2028 |
| NCT07360314 | M7437 | Phase 1 | Advanced Solid Tumors | Oncology | Sep 2028 |
| NCT04396223 | Avelumab | Phase 1 | Gestational Trophoblastic Neoplasias (GTN) | Oncology | Oct 2028 |
| NCT03944941 | Avelumab | Phase 2 | Skin Squamous Cell Carcinoma | Oncology | Dec 2028 |
| NCT03271372 | Avelumab | Phase 3 | Stage III Merkel Cell Carcinoma AJCC v8 | Oncology | Jan 2029 |
| NCT07166601 | M0324 | Phase 1 | Advanced Solid Tumor | Oncology | Feb 2029 |
The 60 nearest readouts of 73 trials; the rest in the app.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai Henlius Biotech Sichuan Kelun-Biotech Biopharmaceutical Shenyang Sunshine Pharmaceutical Shanghai Hengrui Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.